The Food and Drug Administration recently granted Gilead Sciences (GILD +1.91%) priority review for its much-awaited hepatitis C drug sofosbuvir. Current treatments are far from perfect for the 3.2 million people suffering from chronic forms of the disease. This novel oral therapy has a lot going for it, which has some analysts thinking it could potentially hit $5 billion in peak sales. In the following video, Fool contributor Maxx Chatsko explains how Gilead's drug raises the bar for the future of hepatitis C treatment.
Gilead's Potential Megablockbuster Raises the Bar
By Maxx Chatsko – Jun 16, 2013 at 9:20AM
NASDAQ: GILD
Gilead Sciences
Market Cap
$149B
Today's Change
(1.91%) $2.29
Current Price
$122.08
Price as of November 3, 2025 at 3:58 PM ET
Gilead's sofosbuvir will get priority review, which brings it one step closer to upping the bar in hepatitis C treatment.
About the Author
Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.